

Synthesis and cytotoxic activities of novel 4-methoxy-substituted and 5-methyl-substituted (3'S,4'S)-(-)-cis-khellactone derivatives that induce apoptosis via the intrinsic pathway

Jingrun Chen^{1,*}Junjie Liu^{1,*}Dongxiao Cui¹Chaoqun Yan¹Liqiang Meng¹Liqian Sun¹Shurong Ban¹Rui Ge¹Taigang Liang^{1,2}Qingshan Li^{1,2}

¹Laboratory of Medicinal Chemistry, School of Pharmaceutical Science, Shanxi Medical University, ²College of Traditional Chinese Medicine, Shanxi University of Traditional Chinese Medicine, Taiyuan, Shanxi, People's Republic of China

*These authors contributed equally to this work

Abstract: This study deals with the design and synthesis of a series of novel 4-methoxy-substituted and 5-methyl-substituted (3'S,4'S)-(-)-cis-khellactones. The newly synthesized compounds were characterized by ¹H nuclear magnetic resonance (NMR), ¹³C-NMR, mass spectrometry, and elemental analysis. All the derivatives were subjected to in vitro cytotoxicity screening against HEPG-2 (human liver carcinoma), SGC-7901 (human gastric carcinoma), and LS174T (human colon carcinoma), by using the MTT assay. The results revealed that several of the 4-methoxy-substituted compounds exhibited potent cytotoxicity. Among these, compound **12e** showed the highest activity against cancer cells which 50% inhibitory concentration (IC₅₀) values were in the range of 6.1–9.2 μM with low toxicity on normal human hepatocyte. Preliminary investigation of possible mechanisms of action of compound **12e** against HEPG-2 cells indicated possible induction of apoptosis, as determined by morphological observations and Annexin V/propidium iodide (PI) double staining, in addition to apparent dissipation of mitochondrial membrane potential (MMP), as measured by 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethyl-imidacarbocyanine iodide (JC-1) staining in combination with the activation of caspase-9 and caspase-3 by Western blot analysis. Overall, the data suggest that compound **12e** may be a promising potential anti-cancer agent that could act primarily by inducing apoptosis through the mitochondria-mediated intrinsic pathway in human hepatoma cells.

Keywords: 4-methoxy-substituted and 5-methyl-substituted (3'S,4'S)-(-)-cis-khellactones, synthesis, cytotoxic activity, apoptosis

Abbreviations

AO, acridine orange; (DHQD)2-PYR, hydroquinidine-2,5-diphenyl-4,6-pyrimidinediyl diether; DMEM, Dulbecco's Modified Eagle's Medium; DMSO, dimethyl sulfoxide; EB, ethidium bromide; ECL, enhanced chemiluminescence; ee, enantiomeric excess; ESI, electrospray ionization; FBS, fetal bovine serum; FITC, fluorescein isothiocyanate; HPLC, high-performance liquid chromatography; HRP, horseradish peroxidase; IC₅₀, 50% inhibitory concentration; JC-1, 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethyl-imidacarbocyanine iodide; MMP, mitochondrial membrane potential; NMR, nuclear magnetic resonance; PE, petroleum ether; PI, propidium iodide; ppm, parts per million; RIPA, radio-immunoprecipitation assay; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis; TBS-T, tris-buffered saline plus Tween-20; TLC, thin-layer chromatography; TMS, tetramethylsilane.

Correspondence: Taigang Liang; Qingshan Li
Laboratory of Medicinal Chemistry, School of Pharmaceutical Science, Shanxi Medical University, No 56, Xinjian Nan Road, Taiyuan 030001, Shanxi, People's Republic of China
Tel/fax +86 351 469 0322
Email litaigang@163.com; sxlqs2012@163.com

Introduction

Cancer is now a leading cause of mortality worldwide and was responsible for 8.2 million deaths in 2012.¹ In addition to surgery and radiation therapy, chemotherapy remains an important and widely used treatment option for many human malignancies.^{2,3} Although considerable advances have been made in chemotherapy over the past several decades, there is still an urgent need for novel chemotherapeutic agents with higher efficacy and lower toxicity. It is well known that a number of clinically useful chemotherapeutic agents such as taxol, topotecan, and irinotecan have been derived from naturally occurring small organic molecules.⁴

Coumarins comprise a large class of natural compounds found throughout the plant kingdom. Natural and synthetic coumarin derivatives exhibit a wide range of pharmacological actions, such as antimicrobial, antiviral, anticancer, anti-inflammatory, antioxidant, anticoagulant, and central nervous system activities, and are therefore considered to be ideal lead compounds for drug development.^{5–7} Khellactone, a member of the coumarin family, possesses a pyrano ring fused at positions seven and eight of the coumarin molecular skeleton and is regarded as a biosynthetic pioneer found originally in plants with the angular-type pyranocoumarin. Natural khellactone coumarins have been mainly isolated from *Peucedanum* species.^{8–10} In the past 2 decades, khellactone and its derivatives have attracted great interest in medicinal chemistry owing to their wide range of biological effects including antiviral activity,¹¹ inhibition of platelet aggregation,¹² calcium antagonist activity,¹³ and inhibition of P-glycoprotein.^{14,15} In particular, attention has been focused primarily on their anti-HIV activity, and some khellactone derivatives have been found to demonstrate extremely potent inhibitory activity against HIV-1 replication.^{16,17} It is notable that khellactone coumarins contain two chiral carbons of C-3' and C-4' (Figure 1), and previous studies showed that 3'*R*- and 4'*R*-configured khellactone derivatives are critical for anti-HIV activity.^{18–20}

In previous studies, we synthesized the amount of 4-methyl-(3'*S*,4'*S*)-(-)-*cis*-khellactone derivatives by using

a chiral catalyst of (DHQD)₂-PYR. Some of the synthesized derivatives exhibited considerable inhibition of human cancer cells, and this finding prompted us to further explore *cis*-khellactone derivatives with the 3'*S*,4'*S* configuration as new potential anticancer agents.²¹ This study deals with the design and synthesis of a new series of substituted (3'*S*,4'*S*)-(-)-*cis*-khellactone. The derivatives were evaluated for their in vitro antitumor activity against three human cancer cell lines (HEPG-2, SGC-7901, and LS174T). In addition, compound **12e**, which exhibited the highest activity against the HEPG-2 cancer cell line, was further investigated in an attempt to obtain insight into the primary mechanism of antitumor action of this class of agents.

Materials and methods

Materials

Melting points were measured on an XT-4 melting point apparatus without correction. NMR spectra were generated on a BRUKER AVANCE-600 spectrometer and obtained as CDCl₃ or DMSO-*d*₆ solutions (600 MHz for ¹H and 150 MHz for ¹³C). Chemical shifts are reported as δ values in ppm relative to TMS, and *J* values are expressed in Hertz. ESI mass spectra were determined in an API QTRAP 3200 LC-MS spectrometer. The elemental analyses were performed by using an Elementar Vario-III CHN analyzer and were within $\pm 0.4\%$ of theoretical values. Optical rotations were measured on Perkin-Elmer 241 polarimeter in a 1-dm cell. The Chiralpak AS-H chiral HPLC analysis by using Shimadzu LC-10A instrument was applied to detect the ee values of the compounds. TLC analysis of reaction mixtures was carried out on silica gel GF-254 (Qingdao Ocean Chemical Factory, Qingdao, China), and the identification was performed under ultraviolet (UV) light. Silica gel (200–300 mesh) used in column chromatography was provided by Tsingtao Marine Chemistry Co. Ltd (Qingdao, China). Chiral catalyst (DHQD)₂-PYR was procured from Sigma-Aldrich Co. (St Louis, MO, USA). Other commercial chemicals were purchased from Aladdin Chemicals Co. (Shanghai, China) and used without further purification. Compounds **2**, **3**, **4**, **6**, and **7** were synthesized according to previously reported procedure.¹⁸

Synthesis of compounds

General method for the preparation of substituted seselins (**8**, **9**)

Compounds **8** and **9** were synthesized according to previous literature, and the melting points of these two compounds were reported to be 167°C–168°C and 143°C–144°C, respectively.¹⁸ To a stirred solution of substituted 7-hydroxycoumarins **4**, **7** (10 mmol) and potassium carbonate (3.45 g, 25 mmol) in




Figure 1 Structures of *cis*-khellactone with 3'*R*,4'*R* and 3'*S*,4'*S* configuration.

N,N-dimethylformamide (20 mL), potassium iodide (1.66 g, 10 mmol) was added, followed by adding excess 3-chloro-3-methyl-1-butyne (6 mL). The stirred reaction mixture was warmed at 70°C–80°C for 72 h. Then, the solution was filtered and the solvent was evaporated in vacuo. The residue was directly added in 20 mL of *N,N*-diethylaniline, refluxed for 15 h. The mixture cooled down was diluted by 20 mL ethyl acetate, and successively washed using 10% aqueous hydrochloric acid, water, and brine. The solvent was removed under reduced pressure. The crude product was further purified by silica gel column chromatography (PE/ethyl acetate: 10/1) to obtain compounds **8** and **9**.

4-Methoxyseselin (**8**)

Light yellow solid; yield, 41%; m.p., 162°C–164°C. ¹H-NMR (600 MHz, CDCl₃, ppm) δ 1.44 (s, 6H, C-2'-CH₃), 3.94 (s, 3H, C-4-OCH₃), 5.53 (s, 1H, H-3), 5.68 (d, 1H, *J*=10.02 Hz, H-3'), 6.68 (d, 1H, *J*=8.68 Hz, H-6), 6.85 (d, 1H, *J*=10.02 Hz, H-4'), 7.51 (d, 1H, *J*=8.68 Hz, H-5). MS (ESI) *m/z* 280.9 ([M+Na]⁺). Anal. Calc for C₁₅H₁₄O₄: C, 69.76%; H, 5.46%. Found: C, 69.71%; H, 5.40%.

5-Methylseselin (**9**)

White solid; yield, 21%; m.p., 145°C–146°C. ¹H-NMR (600 MHz, CDCl₃, ppm) δ 1.46 (s, 6H, C-2'-CH₃), 2.43 (s, 3H, C-5-CH₃), 5.66 (d, 1H, *J*=10.05 Hz, H-3'), 6.22 (d, 1H, *J*=9.69 Hz, H-3), 6.58 (s, 1H, H-6), 6.86 (d, 1H, *J*=10.05 Hz, H-4'), 7.80 (d, 1H, *J*=9.69 Hz, H-4). MS (ESI) *m/z* 265.0 ([M+Na]⁺). Anal. Calc for C₁₅H₁₄O₃: C, 74.36%; H, 5.82%. Found: C, 74.40%; H, 5.89%.

General procedure for the preparation of substituted (3'S,4'S)-(-)-*cis*-khellactone (**10**, **11**)

Potassium carbonate (105 mg, 0.75 mmol) was added to a solution of potassium ferricyanide (246 mg, 0.75 mmol) in tert-butanol/water (1:1, v/v) (5 mL), and the mixture was stirred for 5 min. Potassium osmate (2 mg, 0.005 mmol) and (DHQD)₂-PYR (4.4 mg, 0.005 mmol) were then added, and continuously stirred for 15 min. Then, the mixture was cooled to 0°C and methane sulfonamide (24 mg, 0.25 mmol) was added under stirring. When the color of solution turned from a light yellow to an orange, substituted seselin (0.25 mmol) was added, and the mixture was stirred at 0°C for approximately 24 h. TLC analysis monitored the progress of reaction. After completion of the reaction as indicated on TLC, the contents such as dichloromethane (2.5 mL), sodium pyrosulfite (1 g), and water (2.5 mL) were added. The mixture was continuously stirred for another 4 h at room temperature, and then extracted with dichloromethane (3×15 mL). The organic

layer was dried with anhydrous sodium sulfate and evaporated in vacuo. The crude product was purified by column chromatography using the PE/ethyl acetate (6:1, v/v) to obtain substituted (3'S,4'S)-(-)-*cis*-khellactone **10** and **11**.

4-Methoxy-(3'S,4'S)-(-)-*cis*-khellactone (**10**)

White solid; yield, 51%; m.p., 218°C–220°C; [α]_{D20}=-42.6 (*c* 0.3, CHCl₃). ee =86%, Chiral Pak AS-H column eluting with hexane/isopropanol (90:10, v:v), flow rate=0.8 mL/min, wavelength =323 nm, *t_R* (minor) =26.21 min, *t_R* (major) =38.91 min; ¹H-NMR (600 MHz, DMSO-*d*₆, ppm) δ 1.34 (s, 3H, C-2'-CH₃), 1.36 (s, 3H, C-2'-CH₃), 3.60 (br, 1H, H-4'), 3.96 (s, 3H, C-4-OCH₃), 4.88 (br, 1H, H-3'), 5.19 (br, 2H, OH×2), 5.72 (s, 1H, H-3), 6.73 (d, 1H, *J*=8.79 Hz, H-6), 7.57 (d, 1H, *J*=8.79 Hz, H-5). ¹³C-NMR (150 MHz, DMSO-*d*₆) δ 20.99, 26.87, 56.78, 60.24, 71.18, 78.77, 87.13, 107.68, 111.65, 113.44, 123.07, 153.13, 156.08, 161.96, 166.34. MS (ESI) *m/z* 314.8 ([M+Na]⁺). Anal. Calc for C₁₅H₁₆O₆: C, 61.64%; H, 5.52%. Found: C, 61.73%; H, 5.44%.

5-Methyl-(3'S,4'S)-(-)-*cis*-khellactone (**11**)

White solid; yield, 46%; m.p., 178°C–180°C; [α]_{D20}=-41.5 (*c* 0.2, CHCl₃). ee =87%, Chiral Pak AS-H column eluting with hexane/isopropanol (90:10, v:v), flow rate=0.8 mL/min, wavelength =323 nm, *t_R* (minor) =32.58 min, *t_R* (major) =79.50 min; ¹H-NMR (600 MHz, DMSO-*d*₆, ppm) δ 1.33 (s, 3H, C-2'-CH₃), 1.35 (s, 3H, C-2'-CH₃), 2.40 (s, 3H, C-5-CH₃), 3.58 (br m, 1H, H-4'), 4.86 (br m, 1H, H-3'), 5.14 (br, 2H, OH×2), 6.24 (d, 1H, *J*=9.67 Hz, H-3), 6.61 (s, 1H, H-6), 8.05 (d, 1H, *J*=9.67 Hz, H-4). ¹³C-NMR (150 MHz, DMSO-*d*₆) δ 17.80, 21.02, 26.88, 60.05, 71.28, 78.70, 109.62, 110.86, 111.04, 114.61, 137.20, 141.72, 154.49, 155.33, 160.20; MS (ESI) *m/z* 277.0 ([M+H]⁺). Anal. Calc for C₁₅H₁₆O₅: C, 65.21%; H, 5.84%. Found: C, 65.14%; H, 5.89%.

General method for the preparation of substituted (±)-*cis*-khellactone (**10'**, **11'**)

Substituted seselin (1 mmol) was added to a mixture solution of *N*-methylmorpholine-*N*-oxide monohydrate (0.129 g, 1.1 mmol) and osmium tetroxide (10 mg, 0.04 mmol) which were dissolved in tert-butanol/tetrahydrofuran/water (10/3/1, 10 mL); the mixture was stirred for 24 h at room temperature. Then, saturated sodium hydrogen sulfite solution was added (80 mL) to keep stirring for another 2 h and was diluted with dichloromethane (80 mL). The organic layer was dried by using sodium sulfate and then evaporated to dryness under reduced pressure. Purification by column chromatography (PE/acetone: 5/1) obtained the substituted (±)-*cis*-khellactone **10'** and **11'**.

4-Methoxy-(±)-cis-khellactone (10')

White solid; yield, 63%; m.p., 228°C–230°C. ¹H-NMR (600 MHz, DMSO-*d*₆, ppm) δ 1.34 (s, 3H, C-2'-CH₃), 1.36 (s, 3H, C-2'-CH₃), 3.58 (br, 1H, H-4'), 3.97 (s, 3H, C-4-OCH₃), 4.89 (br, 1H, H-3'), 5.20 (br, 2H, OH×2), 5.72 (s, 1H, H-3), 6.74 (d, 1H, *J*=8.79 Hz, H-6), 7.58 (d, 1H, *J*=8.79 Hz, H-5). MS (ESI) *m/z* 314.6 ([M+Na]⁺). Anal. Calc for C₁₅H₁₆O₆: C, 61.64%; H, 5.52%. Found: C, 61.71%; H, 5.58%.

5-Methyl-(±)-cis-khellactone (11')

White solid; yield, 58%; m.p., 185°C–187°C; ¹H-NMR (600 MHz, DMSO-*d*₆, ppm) δ 1.33 (s, 3H, C-2'-CH₃), 1.35 (s, 3H, C-2'-CH₃), 2.40 (s, 3H, C-5-CH₃), 3.57 (br m, 1H, H-4'), 4.85 (br m, 1H, H-3'), 5.12 (br, 2H, OH×2), 6.22 (d, 1H, *J*=9.67 Hz, H-3), 6.60 (s, 1H, H-6), 8.03 (d, 1H, *J*=9.67 Hz, H-4). MS (ESI) *m/z* 277.0 ([M+H]⁺). Anal. Calc for C₁₅H₁₆O₅: C, 65.21%; H, 5.84%. Found: C, 65.15%; H, 5.91%.

General procedure for the preparation of (3'S,4'S)-(-)-cis-khellactone derivatives (12a–g, 13a–g)

Excess acylating agent was added to a solution of substituted (3'S,4'S)-(-)-cis-khellactone (0.2 mmol) in anhydrous pyridine (1 mL) and dichloromethane (2 mL) at 0°C, and refluxed until completed by TLC monitor. The mixture was filtered, and the filtrate was evaporated in vacuo. Purification by column chromatography (PE/acetone: 10/1) obtained target compounds.

3'S,4'S-di-O-acetyl-4-methoxy-(-)-cis-khellactone (12a)

White solid; yield, 50%; m.p., 213°C–215°C; [α]_{D20}=+19.8 (*c* 0.2, CH₂Cl₂). ¹H-NMR (600 MHz, DMSO-*d*₆, ppm) δ 1.40 (s, 3H, C-2'-CH₃), 1.44 (s, 3H, C-2'-CH₃), 2.10 (s, 3H, CH₃CO), 2.12 (s, 3H, CH₃CO), 3.95 (s, 3H, C-4-OCH₃), 5.29 (d, 1H, *J*=4.87 Hz, H-3'), 5.55 (s, 1H, H-3), 6.51 (d, 1H, *J*=4.87 Hz, H-4'), 6.78 (d, 1H, *J*=8.89 Hz, H-6), 7.69 (d, 1H, *J*=8.89 Hz, H-5). ¹³C-NMR (150 MHz, DMSO-*d*₆) δ 20.55, 20.59, 22.52, 24.89, 56.19, 60.99, 70.25, 77.36, 87.63, 106.50, 109.01, 113.81, 124.43, 153.13, 156.95, 161.96, 166.50, 169.92. MS (ESI) *m/z* 398.8 ([M+Na]⁺). Anal. Calc for C₁₉H₂₀O₈: C, 60.63%; H, 5.36%. Found: C, 60.61%; H, 5.32%.

3'S,4'S-di-O-methoxyacetyl-4-methoxy-(-)-cis-khellactone (12b)

White solid; yield, 43%; m.p., 116°C–118°C; [α]_{D20}=+6.5 (*c* 0.2, CH₂Cl₂). ¹H-NMR (600 MHz, CDCl₃, ppm) δ 1.42 (s, 3H, C-2'-CH₃), 1.43 (s, 3H, C-2'-CH₃), 3.46 (s, 3H, OCH₃),

3.47 (s, 3H, OCH₃), 3.95 (s, 3H, C-4-OCH₃), 4.05 (m, 4H, 2× CH₂), 5.42 (d, 1H, *J*=4.85 Hz, H-3'), 5.53 (s, 1H, H-3), 6.60 (d, 1H, *J*=4.85 Hz, H-4'), 6.79 (d, 1H, *J*=8.89 Hz, H-6), 7.70 (d, 1H, *J*=8.89 Hz, H-5). ¹³C-NMR (150 MHz, CDCl₃) δ 22.42, 24.91, 56.25, 59.41, 59.47, 61.44, 69.32, 69.54, 70.54, 87.64, 105.89, 109.09, 113.88, 124.77, 153.06, 156.85, 161.80, 166.46, 169.56, 169.69. MS (ESI) *m/z* 458.8 ([M+Na]⁺). Anal. Calc for C₂₁H₂₄O₁₀: C, 57.80%; H, 5.54%. Found: C, 57.76%; H, 5.48%.

3'S,4'S-di-O-benzoyl-4-methoxy-(-)-cis-khellactone (12c)

White solid; yield, 42%; m.p., 242°C–244°C; [α]_{D20}=-3.3 (*c* 0.1, CH₂Cl₂). ¹H-NMR (600 MHz, CDCl₃, ppm) δ 1.51 (s, 3H, C-2'-CH₃), 1.64 (s, 3H, C-2'-CH₃), 3.93 (s, 3H, C-4-OCH₃), 5.50 (1H, s, H-3), 5.67 (d, 1H, *J*=4.92 Hz, H-3'), 6.88 (d, 1H, *J*=8.92 Hz, H-6), 6.95 (d, 1H, *J*=4.92 Hz, H-4'), 7.33 (m, 4H, Ar-H), 7.51 (m, 2H, Ar-H), 7.75 (d, 1H, *J*=8.92 Hz, H-5), 7.87 (m, 4H, Ar-H). ¹³C-NMR (150 MHz, CDCl₃) δ 22.37, 25.61, 56.18, 61.24, 71.17, 77.43, 87.85, 106.84, 109.08, 113.91, 124.75, 128.19, 128.31, 129.31, 129.78, 132.79, 133.22, 153.35, 157.09, 161.71, 165.25, 166.31. MS (ESI) *m/z* 522.8 ([M+Na]⁺). Anal. Calc for C₂₉H₂₄O₈: C, 69.59%; H, 4.83%. Found: C, 69.62%; H, 4.77%.

3'S,4'S-di-O-(2-methoxybenzoyl)-4-methoxy-(-)-cis-khellactone (12d)

White solid; yield, 38%; m.p., 167°C–169°C; [α]_{D20}=-9.6 (*c* 0.2, CH₂Cl₂). ¹H-NMR (600 MHz, CDCl₃, ppm) δ 1.52 (s, 3H, C-2'-CH₃), 1.58 (s, 3H, C-2'-CH₃), 3.70 (s, 3H, OCH₃), 3.76 (s, 3H, OCH₃), 3.91 (s, 3H, C-4-OCH₃), 5.50 (s, 1H, H-3), 5.65 (d, 1H, *J*=4.94 Hz, H-3'), 6.81 (d, 1H, *J*=8.89 Hz, H-6), 6.86 (m, 4H, Ar-H), 6.92 (d, 1H, *J*=4.94 Hz, H-4'), 7.38 (m, 2H, Ar-H), 7.69 (d, 1H, *J*=8.89 Hz, H-5), 7.69 (m, 2H, Ar-H). ¹³C-NMR (150 MHz, CDCl₃) δ 22.07, 25.67, 55.64, 55.68, 56.12, 60.93, 70.94, 77.53, 87.67, 107.22, 108.84, 111.79, 113.80, 119.35, 119.92, 119.95, 120.64, 124.43, 131.30, 132.02, 132.80, 133.57, 153.29, 157.05, 158.74, 159.37, 161.79, 164.76, 165.20, 166.30. MS (ESI) *m/z* 582.7 ([M+Na]⁺). Anal. Calc for C₃₁H₂₈O₁₀: C, 66.42%; H, 5.03%. Found: C, 66.35%; H, 4.94%.

3'S,4'S-di-O-(2-chlorobenzoyl)-4-methoxy-(-)-cis-khellactone (12e)

White solid; yield, 48%; m.p., 221°C–222°C; [α]_{D20}=-33.3 (*c* 0.1, CH₂Cl₂). ¹H-NMR (600 MHz, CDCl₃, ppm) δ 1.57 (s, 3H, C-2'-CH₃), 1.58 (s, 3H, C-2'-CH₃), 3.95 (s, 3H, C-4-OCH₃), 5.54 (s, 1H, H-3), 5.71 (d, 1H, *J*=4.92 Hz, H-3'),

6.84 (d, 1H, $J=8.96$ Hz, H-6), 6.93 (d, 1H, $J=4.92$ Hz, H-4'), 7.20 (m, 1H, Ar-H), 7.36 (m, 5H, Ar-H) 7.72 (m, 1H, Ar-H), 7.73 (d, 1H, $J=8.96$ Hz, H-5), 7.86 (m, 1H, Ar-H). $^{13}\text{C-NMR}$ (150 MHz, CDCl_3) δ 22.13, 25.86, 56.22, 61.99, 72.00, 77.42, 87.81, 106.61, 109.05, 113.99, 124.89, 126.49, 126.62, 129.65, 130.46, 130.83, 131.12, 132.05, 132.69, 133.01, 133.52, 153.31, 157.03, 161.75, 164.75, 165.18, 166.42. MS (ESI) m/z 592.6 ($[\text{M}+\text{Na}]^+$). Anal. Calc for $\text{C}_{29}\text{H}_{22}\text{Cl}_2\text{O}_8$: C, 61.17%; H, 3.89%. Found: C, 61.15%; H, 3.81%.

3'S,4'S-di-O-(3-chlorobenzoyl)-4-methoxy-(–)-cis-khellactone (**12f**)

White solid; yield, 43%; m.p., 200°C–201°C; $[\alpha]_{\text{D}_{20}}=-9.6$ (c 0.1, CH_2Cl_2). $^1\text{H-NMR}$ (600 MHz, CDCl_3 , ppm) δ 1.50 (s, 3H, C-2'- CH_3), 1.62 (s, 3H, C-2'- CH_3), 3.94 (s, 3H, C-4- CH_3O), 5.51 (s, 1H, H-3), 5.65 (d, 1H, $J=4.94$ Hz, H-3'), 6.89 (d, 1H, $J=8.92$ Hz, H-6), 6.91 (d, 1H, $J=4.94$ Hz, H-4'), 7.30 (m, 2H, Ar-H), 7.50 (m, 2H, Ar-H), 7.77 (d, 1H, $J=8.92$ Hz, H-5), 7.78 (m, 4H, Ar-H). $^{13}\text{C-NMR}$ (150 MHz, CDCl_3) δ 22.48, 25.36, 56.24, 61.67, 71.38, 77.29, 87.85, 106.23, 109.19, 113.97, 124.99, 127.89, 127.99, 129.65, 129.70, 129.77, 130.84, 131.30, 133.05, 133.44, 134.39, 134.57, 153.25, 156.99, 161.70, 164.15, 164.20, 166.33. MS (ESI) m/z 592.1 ($[\text{M}+\text{Na}]^+$). Anal. Calc for $\text{C}_{29}\text{H}_{22}\text{Cl}_2\text{O}_8$: C, 61.17%; H, 3.89%. Found: C, 61.20%; H, 3.84%.

3'S,4'S-di-O-(4-chlorobenzoyl)-4-methoxy-(–)-cis-khellactone (**12g**)

White solid; yield, 46%; m.p., 273°C–275°C; $[\alpha]_{\text{D}_{20}}=-22.4$ (c 0.2, CH_2Cl_2). $^1\text{H-NMR}$ (600 MHz, CDCl_3 , ppm) δ 1.50 (s, 3H, C-2'- CH_3), 1.60 (s, 3H, C-2'- CH_3), 3.93 (s, 3H, C-4- OCH_3), 5.50 (s, 1H, H-3), 5.64 (d, 1H, $J=4.98$ Hz, H-3'), 6.88 (d, 1H, $J=8.99$ Hz, H-6), 6.89 (d, 1H, $J=4.98$ Hz, H-4'), 7.32 (m, 4H, Ar-H), 7.75 (d, 1H, $J=8.99$ Hz, H-5), 7.79 (m, 4H, Ar-H). $^{13}\text{C-NMR}$ (150 MHz, CDCl_3) δ 22.53, 25.35, 56.22, 61.66, 71.27, 77.36, 87.83, 106.40, 109.18, 113.93, 124.89, 128.65, 128.78, 131.07, 139.44, 139.88, 153.29, 157.03, 161.66, 164.42, 164.49, 166.33. MS (ESI) m/z 592.3 ($[\text{M}+\text{Na}]^+$). Anal. Calc for $\text{C}_{29}\text{H}_{22}\text{Cl}_2\text{O}_8$: C, 61.17%; H, 3.89%. Found: C, 61.13%; H, 3.82%.

3'S,4'S-di-O-acetyl-5-methyl-(–)-cis-khellactone (**13a**)

White solid; yield, 48%; m.p., 202°C–204°C; $[\alpha]_{\text{D}_{20}}=8.4$ (c 0.2, CH_2Cl_2). $^1\text{H-NMR}$ (600 MHz, CDCl_3 , ppm) δ 1.39 (s, 3H, C-2'- CH_3), 1.43 (s, 3H, C-2'- CH_3), 2.09 (s, 3H, CH_3CO), 2.11 (s, 3H, CH_3CO), 2.45 (s, 3H, C-5- CH_3), 5.27 (d, 1H, $J=4.74$ Hz, H-3'), 6.24 (d, 1H, $J=9.72$ Hz, H-3), 6.49 (d, 1H, $J=4.74$ Hz, H-4'), 6.65 (s, 1H, H-6), 7.79

(d, 1H, $J=9.72$ Hz, H-4). $^{13}\text{C-NMR}$ (150 MHz, CDCl_3) δ 18.37, 20.57, 20.61, 22.54, 24.93, 60.87, 70.33, 77.34, 104.69, 111.73, 112.45, 115.27, 137.93, 140.18, 154.44, 156.14, 159.86, 169.93. MS (ESI) m/z 382.7 ($[\text{M}+\text{Na}]^+$). Anal. Calc for $\text{C}_{19}\text{H}_{20}\text{O}_7$: C, 63.33%; H, 5.59%. Found: C, 63.30%; H, 5.53%.

3'S,4'S-di-O-methoxyacetyl-5-methyl-(–)-cis-khellactone (**13b**)

White solid; yield, 43%; m.p., 117°C–118°C; $[\alpha]_{\text{D}_{20}}=11.4$ (c 0.2, CH_2Cl_2). $^1\text{H-NMR}$ (600 MHz, CDCl_3 , ppm) δ 1.41 (s, 3H, C-2'- CH_3), 1.42 (s, 3H, C-2'- CH_3), 2.45 (s, 3H, C-5- CH_3), 3.45 (3H, s, OCH_3), 3.46 (3H, s, OCH_3), 4.08 (4H, m, $2\times \text{CH}_2$), 5.39 (1H, d, $J=4.82$ Hz, H-3'), 6.22 (1H, d, $J=9.76$ Hz, H-3), 6.57 (1H, d, $J=4.82$ Hz, H-4'), 6.65 (1H, s, H-6), 7.78 (1H, d, $J=9.76$ Hz, H-4). $^{13}\text{C-NMR}$ (150 MHz, CDCl_3) δ 18.40, 22.37, 25.00, 59.40, 59.44, 61.32, 69.35, 69.55, 70.68, 104.12, 111.78, 112.55, 115.32, 138.31, 140.17, 154.41, 156.05, 159.65, 169.54, 169.71. MS (ESI) m/z 442.8 ($[\text{M}+\text{Na}]^+$). Anal. Calc for $\text{C}_{21}\text{H}_{24}\text{O}_9$: C, 59.99%; H, 5.75%. Found: C, 59.94%; H, 5.81%.

3'S,4'S-di-O-benzoyl-5-methyl-(–)-cis-khellactone (**13c**)

White solid; yield, 41%; m.p., 208°C–210°C; $[\alpha]_{\text{D}_{20}}=-14.3$ (c 0.1, CH_2Cl_2). $^1\text{H-NMR}$ (600 MHz, CDCl_3 , ppm) δ 1.50 (s, 3H, C-2'- CH_3), 1.64 (s, 3H, C-2'- CH_3), 2.49 (s, 3H, C-5- CH_3), 5.65 (d, 1H, $J=4.93$ Hz, H-3'), 6.18 (d, 1H, $J=9.76$ Hz, H-3), 6.75 (s, 1H, H-6), 6.93 (d, 1H, $J=4.93$ Hz, H-4'), 7.33 (m, 4H, Ar-H), 7.50 (m, 2H, Ar-H), 7.78 (d, 1H, $J=9.76$ Hz, H-4), 7.88 (m, 4H, Ar-H). $^{13}\text{C-NMR}$ (150 MHz, CDCl_3) δ 18.50, 22.36, 25.64, 61.06, 71.22, 77.38, 104.97, 111.75, 112.69, 115.36, 128.19, 128.31, 129.25, 129.76, 129.80, 132.81, 133.24, 138.27, 139.99, 154.59, 156.22, 159.63, 165.26, 165.30. MS (ESI) m/z 507.2 ($[\text{M}+\text{Na}]^+$). Anal. Calc for $\text{C}_{29}\text{H}_{24}\text{O}_7$: C, 71.89%; H, 4.99%. Found: C, 71.86%; H, 4.90%.

3'S,4'S-di-O-(2-methoxybenzoyl)-5-methyl-(–)-cis-khellactone (**13d**)

White solid; yield, 39%; m.p., 196°C–198°C; $[\alpha]_{\text{D}_{20}}=-49.9$ (c 0.2, CH_2Cl_2). $^1\text{H-NMR}$ (600 MHz, CDCl_3 , ppm) δ 1.51 (s, 3H, C-2'- CH_3), 1.58 (s, 3H, C-2'- CH_3), 2.46 (s, 3H, C-5- CH_3), 3.71 (s, 3H, OCH_3), 3.78 (s, 3H, OCH_3), 5.64 (d, 1H, $J=4.95$ Hz, H-3'), 6.20 (d, 1H, $J=9.76$ Hz, H-3), 6.68 (s, 1H, H-6), 6.88 (d, 1H, $J=4.95$ Hz, H-4'), 6.88 (m, 4H, Ar-H); 7.37 (m, 1H, Ar-H), 7.42 (m, 1H, Ar-H), 7.68 (m, 1H, Ar-H), 7.77 (d, 1H, $J=9.76$ Hz, H-4), 7.79 (m, 1H, Ar-H). $^{13}\text{C-NMR}$

(150 MHz, CDCl_3) δ 18.45, 22.12, 25.75, 55.67, 55.73, 60.83, 71.04, 77.56, 105.44, 105.48, 111.61, 111.79, 111.85, 112.55, 131.29, 132.06, 132.79, 132.84, 133.55, 133.61, 137.96, 139.94, 140.00, 154.62, 156.27, 158.77, 159.40, 159.67, 159.73, 164.80, 165.28. MS (ESI) m/z 567.1 ($[\text{M}+\text{Na}]^+$). Anal. Calc for $\text{C}_{31}\text{H}_{28}\text{O}_9$: C, 68.37%; H, 5.18%. Found: C, 68.33%; H, 5.26%.

3'S,4'S-di-O-(2-chlorobenzoyl)-5-methyl-(–)-cis-khellactone (**13e**)

White solid; yield, 46%; m.p., 188°C–190°C; $[\alpha]_{\text{D}_{20}} = -45.1$ (c 0.2, CH_2Cl_2). $^1\text{H-NMR}$ (600 MHz, CDCl_3 , ppm) δ 1.57 (s, 6H, $2\times \text{C-2'-CH}_3$), 2.47 (s, 3H, C-5- CH_3), 5.69 (d, 1H, $J=4.86$ Hz, H-3'), 6.23 (d, 1H, $J=9.77$ Hz, H-3), 6.70 (s, 1H, H-6), 6.91 (d, 1H, $J=4.86$ Hz, H-4'), 7.20 (m, 1H, Ar-H), 7.36 (m, 5H, Ar-H), 7.72 (m, 1H, Ar-H), 7.79 (d, 1H, $J=9.77$ Hz, H-4), 7.86 (m, 1H, Ar-H). $^{13}\text{C-NMR}$ (150 MHz, CDCl_3) δ 18.46, 22.13, 25.92, 61.85, 72.09, 77.38, 104.79, 111.74, 112.68, 115.41, 126.48, 126.62, 130.49, 130.83, 131.06, 132.05, 132.69, 133.02, 133.51, 138.42, 140.07, 140.12, 154.60, 156.18, 159.62, 159.67, 164.75, 165.21; MS (ESI) m/z 576.7 ($[\text{M}+\text{Na}]^+$). Anal. Calc for $\text{C}_{29}\text{H}_{22}\text{Cl}_2\text{O}_7$: C, 62.94%; H, 4.01%. Found: C, 62.91%; H, 4.09%.

3'S,4'S-di-O-(3-chlorobenzoyl)-5-methyl-(–)-cis-khellactone (**13f**)

White solid; yield, 43%; m.p., 190°C–192°C; $[\alpha]_{\text{D}_{20}} = -9.9$ (c 0.2, CH_2Cl_2). $^1\text{H-NMR}$ (600 MHz, CDCl_3 , ppm) δ 1.49 (s, 3H, C-2'- CH_3), 1.61 (s, 3H, C-2'- CH_3), 2.50 (s, 3H, C-5- CH_3), 5.64 (d, 1H, $J=4.95$ Hz, H-3'), 6.20 (d, 1H, $J=9.42$ Hz, H-3), 6.75 (s, 1H, H-6), 6.89 (d, 1H, $J=4.95$ Hz, H-4'), 7.31 (m, 2H, Ar-H), 7.49 (m, 2H, Ar-H), 7.77 (d, 1H, $J=9.42$ Hz, H-4), 7.78 (m, 4H, Ar-H). $^{13}\text{C-NMR}$ (150 MHz, CDCl_3) δ 18.49, 22.51, 25.40, 61.59, 71.50, 77.30, 104.46, 111.89, 112.77, 115.42, 127.89, 127.97, 128.16, 129.63, 129.76, 130.12, 131.37, 133.03, 133.29, 133.43, 134.42, 134.59, 138.51, 140.04, 154.58, 156.19, 159.58, 164.17, 164.26; MS (ESI) m/z 576.6 ($[\text{M}+\text{Na}]^+$). Anal. Calc for $\text{C}_{29}\text{H}_{22}\text{Cl}_2\text{O}_7$: C, 62.94%; H, 4.01%. Found: C, 62.96%; H, 4.05%.

3'S,4'S-di-O-(4-chlorobenzoyl)-5-methyl-(–)-cis-khellactone (**13g**)

White solid; yield, 54%; m.p., 208°C–209°C; $[\alpha]_{\text{D}_{20}} = -37.1$ (c 0.2, CH_2Cl_2). $^1\text{H-NMR}$ (600 MHz, CDCl_3 , ppm) δ 1.49 (s, 3H, C-2'- CH_3), 1.59 (s, 3H, C-2'- CH_3), 2.49 (s, 3H, C-5- CH_3), 5.62 (d, 1H, $J=4.91$ Hz, H-3'), 6.19 (d, 1H, $J=9.92$ Hz, H-3), 6.75 (s, 1H, H-6), 6.87 (d, 1H, $J=4.91$ Hz, H-4'),

7.32 (m, 4H, Ar-H), 7.78 (d, 1H, $J=9.92$ Hz, H-4), 7.79 (m, 4H, Ar-H). $^{13}\text{C-NMR}$ (150 MHz, CDCl_3) δ 18.48, 22.54, 25.39, 61.52, 71.35, 77.34, 104.60, 111.84, 112.75, 115.37, 127.68, 128.16, 128.27, 128.65, 128.78, 131.07, 131.41, 138.41, 139.44, 139.88, 139.99, 154.60, 156.19, 159.51, 164.43, 164.53; MS (ESI) m/z 576.7 ($[\text{M}+\text{Na}]^+$). Anal. Calc for $\text{C}_{29}\text{H}_{22}\text{Cl}_2\text{O}_7$: C, 62.94%; H, 4.01%. Found: C, 62.91%; H, 4.03%.

Cell culture

HEPG-2 (human liver carcinoma), SGC-7901 (human gastric carcinoma), LS174T (human colon carcinoma), and HL-7702 (normal human hepatocyte) cell lines were obtained from the Institute of Biochemistry and Cell Biology, China Academy of Science. The cells were cultured in DMEM, supplemented with 10% (v/v) heat-inactivated FBS, 100 units/mL penicillin, and 100 $\mu\text{g/mL}$ streptomycin at 37°C in a humidified incubator containing 5% carbon dioxide. Cells in logarithmic growth phase were employed for further experiments.

In vitro cytotoxic activity

The potential cytotoxic activity of all the target compounds in vitro was assessed using the MTT assay. Briefly, cells were seeded in 96-well plates at a density of 2×10^4 cells/well. After overnight incubation, the cells were exposed to different concentrations of compounds for 48 h at 37°C in the atmosphere of 5% CO_2 . Following 48 h of treatment, the cells of each well were stained with 25 μL of MTT (5 mg/mL) and were incubated for a further 4 h at 37°C. Then, the media were removed and shaken for 10 min by adding 150 μL DMSO to all the wells. The absorbance values at 570 nm were measured using a microplate reader (Model 680; Bio-Rad Laboratories Inc., Hercules, CA, USA). The IC_{50} values were calculated according to the equation for Boltzmann sigmoidal concentration response curve using the nonlinear regression fitting models (Prism Version 5; GraphPad Software, Inc., La Jolla, CA, USA).

Morphological analysis by AO/EB double staining

Morphological changes induced by compound **12e** were observed by fluorescence microscopy using AO/EB. In brief, HEPG-2 cells were seeded at a density of 1×10^5 cells/well in six-well plates. After attachment, the cells were treated with compound **12e** at 6.0, 12.0, and 24.0 μM for another 24 h; then, the mixture solution containing 100 mg/mL AO and

EB was added for 10 min. The stained cells were washed twice in PBS and observed immediately under fluorescence microscopy (IX-51; Olympus Corporation, Tokyo, Japan).

Annexin V-FITC/PI assay

HEPG-2 cells were seeded at a density of 1×10^5 cells/well in six-well plates and grown in 5% CO₂ at 37°C for 24 h. Then, cells were exposed to 6.0, 12.0, and 24.0 μ M of compound **12e** for 48 h. After incubation, cells were collected and washed twice using cold PBS and resuspended in 200 μ L of binding buffer at 1×10^6 cells/mL. Subsequently, the samples were incubated with 5 μ L of Annexin V-FITC and PI in the dark for 15 min at room temperature and then analyzed by flow cytometry within 1 h on an FACS Calibur (BD, Franklin Lakes, NJ, USA). Each sample had at least 10,000 cells. The experiment was performed three times.

Measurement of MMP

Changes in the MMP were measured using JC-1 dye. Briefly, at the end of the treatment with compound **12e** (6.0, 12.0, and 24.0 μ M) for 48 h, HEPG-2 cells were collected, washed in ice-cold PBS, and incubated with 10 μ g/mL JC-1 for 30 min at 37°C in the dark. After incubation, the stained cells were transferred to a falcon tube and characterized by flow cytometry. The red/green fluorescence ratio of JC-1 was measured using fluorescent plate reader at 529 nm emission (green)/590 nm emission (red). The relative red/green fluorescence ratio in treated HEPG-2 cells was shown graphically as a percentage of red/green fluorescence ratio value of the control group (cells without treatment), which were considered to have 100% MMP.

Western blot analysis

HEPG-2 cells were treated with different concentrations of compound **12e** for 48 h, then collected and washed twice with

ice-cold PBS. Whole-cell extracts were prepared using RIPA lysis buffer, and protein concentrations were measured by BCA Protein Assay kit. Proteins (40 μ g) were resolved on 10% SDS-PAGE gels along with the equal amount of protein molecular weight standards, followed by transferring onto nitrocellulose membranes. The membranes were blocked in TBS-T with 5% nonfat milk for 1.5 h and incubated overnight with specific primary antibodies (for caspase-9, cleaved caspase-3, and β -actin) at 4°C, then incubated with secondary HRP-linked anti-rabbit antibody. Immunodetection was carried out using ECL detection kit. The relative levels of each signaling event to control β -actin were determined by densitometric scanning.


Statistical analysis

All experiments were repeated at least three times. The results are presented as mean \pm standard error of the mean. We used Graph Pad software prism 5.1 for one-way analysis, followed by the Dunnett's test. A value of $P < 0.05$ denoted statistical significance.

Results and discussion


Chemistry

The title compounds derived in this study were obtained by applying the synthetic strategy described in Schemes 1 and 2. The condensation of 1,3-dihydroxybenzene (**1**) which is available by purchasing in the market with cyanoacetic acid in the presence of zinc chloride/hydrogen chloride produces 4-amino-7-hydroxycoumarin (**2**). Subsequent hydrolysis of **2** in 50% sulfuric acid produced 4,7-dihydroxycoumarin (**3**). Then, the 4-hydroxyl group of **3** was selectively methylated to produce 7-hydroxy-4-methoxycoumarin (**4**). To obtain 7-hydroxy-5-methylcoumarin (**7**), Wittig reaction and intramolecular cyclization, which consisted of the reaction of 3,5-dihydroxytoluene (**5**) with phosphorus oxychloride in excess



Scheme 1 Synthesis of substituted 7-hydroxycoumarins **4** and **7**.

Notes: Reagents and conditions: (i) cyanoacetic acid, zinc chloride/hydrogen chloride; (ii) 50% sulfuric acid; (iii) methanol/sulfuric acid; (iv) *N,N*-diethylaniline/phosphorus oxychloride; (v) $\text{Ph}_3\text{P}=\text{CHCOOEt}$.



Scheme 2 Synthesis of (3'S,4'S)-(-)-cis-khellactone derivatives (**12–13**).


Notes: Reagents and conditions: (i) 3-chloro-3-methyl-1-butyne, potassium carbonate, potassium iodide in DMF, 70°C–80°C, 72 h; (ii) *N,N*-diethylaniline, reflux, 15 h; (iii) potassium ferricyanide, potassium carbonate, (DHQD)₂-Pyr, potassium osmate, methane-sulfonamide, in tert-butanol/water (v/v, 1:1) at 0°C, 24 h; (iv) various acyl chlorides, anhydrous dichloromethane, pyridine, 0°C.

Abbreviations: (DHQD)₂-Pyr, hydroquinidine-2,5-diphenyl-4,6-pyrimidinediyl diether; DMF, *N,N*-dimethylformamide.

N,N-dimethylformamide, were used to derive the coumarin nucleus from 2,4-dihydroxy-6-methylbenzaldehyde (**6**). Compound **6** was further reacted with a triphenyl phosphonium ylide ($\text{Ph}_3\text{P} = \text{CHCOOEt}$) in dichloromethane at room temperature and refluxed by heating in xylene without purification to produce **7**. In the presence of anhydrous potassium carbonate and potassium iodide, the substituted 7-hydroxycoumarins **4** and **7** were continuously reacted with 3-chloro-3-methyl-1-butyne in *N,N*-dimethylformamide and then thermal rearrangement occurred in boiling diethylaniline to form substituted seselins (**8**, **9**) according to the procedures published previously.¹⁸ Similar to the process used in the previous asymmetric preparation of 4-methyl-(3'S,4'S)-(-)-cis-khellactone, the substituted (-)-cis-khellactones **10**, **11** with the 3'S,4'S configuration were successfully prepared by the reaction of osmium-catalyzed asymmetric dihydroxylation of the seselins **8** and **9** in the presence of a chiral catalyst, (DHQD)₂-Pyr.²¹ Target compounds **12a–g** and **13a–g** were synthesized by reacting the unpurified forms of compounds **10** and **11**

with various acyl chlorides in the presence of appropriate pyridine, and dichloromethane used as solvent, adapting a previously reported procedure.¹⁸

For the determination of ee, racemic substituted (±)-cis-khellactones (**10'** and **11'**) were produced by oxidizing the substituted seselins **8** and **9** (Scheme 3).²² Chiral HPLC



Scheme 3 Synthesis of substituted (±)-cis-khellactone (**10'**, **11'**).

Note: Reagents and conditions: (i) osmium tetroxide, *N*-methylmorpholine-*N*-oxide monohydrate in tert-butanol/tetrahydrofuran/water (v/v, 10:3:1) at room temperature, 24 h.

analysis revealed that the reactions were highly stereoselective with good ee (>86% ee). (DHQD)₂-PYR resulted primarily in *cis*-diol with an *S, S* configuration.²³

In vitro antitumor activity assays

All the synthesized target compounds (**12a–g** and **13a–g**) are novel and were screened for their preliminary antitumor activity against three human cancer cell lines (HEPG-2, SGC-7901, and LS174T) by using the MTT assay with doxorubicin as a positive reference compound. As shown in Table 1, the substituted (3′*S*,4′*S*)-(–)-*cis*-khellactones **10** and **11** did not show any cytotoxicity, while some 4-methoxy-(3′*S*,4′*S*)-(–)-*cis*-khellactone derivatives exhibited promising in vitro antitumor activity. Among the synthesized derivatives, compounds **12e**, **12f**, and **12g** appeared to be the most potent. The IC₅₀ values for compound **12e** were 6.1, 9.2, and 8.0 μM in HEPG-2, SGC-7901, and LS174T cells, respectively, while the corresponding values for compound **12f** were 13.3, 21.3, and 23.6 μM. The IC₅₀ values of compound **12g** were 8.1, 29.6, and 16.7 μM, respectively, in HEPG-2, SGC-7901, and LS174T cells. It is well known that various cancer cells have different responses to drug or compound. Interestingly, all these three compounds tended to be more sensitive in HEPG-2 cells compared to that in the other two cancer cell lines. For HEPG-2 cells, the introduction of an electron-donating methoxy group in the benzene

ring at 3′ and 4′ positions (**12d**) led to a decrease in activity compared to that of compound **12c**. Conversely, significant activity was observed with 4-methoxy-substituted derivatives having an electron-withdrawing C₁ substituent on the benzoyl moiety at 3′ and 4′ positions (**12e–g**), and the degree of inhibition ranged as follows: 2-Cl > 4-Cl > 3-Cl. Furthermore, the majority of the other compounds in this group showed moderate activity. However, another group of derivatives (**13a–g**) synthesized with 5-methyl substitution did not show promising activity against the three cancer cell lines investigated. These results showed that the 4-methoxy-substituted derivatives possessed greater activity than the 5-methyl-substituted derivatives and that the introduction of a C₁ substituent in the benzoyl moiety at 3′ and 4′ positions of 4-methoxy-(3′*S*,4′*S*)-(–)-*cis*-khellactone plays a key role in enhancing the activity. Furthermore, compound **12e**, which showed the highest activity against cancer cell lines, was chosen to investigate its cytotoxicity in HL-7702 cells, a normal human liver cell line. As shown in Figure S1, cell viability was greater than 90% after treatment with 100 μM compound **12e** for 48 h. These results indicated that compound **12e** is likely to be selectively toxic to liver cancer cell.

Morphological changes of HEPG-2 cell by using AO/EB double-staining assay

To determine whether the cytotoxicity in HEPG-2 cells caused by compound **12e** was related to the induction of apoptosis, morphological observation with AO/EB staining was detected by fluorescence microscopy. As shown in Figure 2, green live cells with normal morphology were seen in the control group, while the cells exposed to compound **12e** showed apoptotic morphological changes such as cell shrinkage, chromatin condensation, cell nuclear fragmentation, and labeled orange color.

Analysis of apoptosis by using the Annexin V-FITC/PI method

To characterize the apoptosis induced by compound **12e**, the Annexin V/PI double-staining method was used to quantify the apoptotic HEPG-2 cells following treatment with 6, 12, and 24 μM of **12e**. The percentage of early apoptotic cells observed at these doses were 13.68%, 26.90%, and 30.72%, respectively, and this was statistically significant compared to 5.91% observed with control cells (*P* < 0.01). Furthermore, total apoptotic cells at the three doses tested were found to be 20.83%, 39.52%, and 43.88% respectively, while the untreated control group had 8.75% of

Table 1 Cytotoxic activity of the synthesized compounds against three human cancer cell lines

Compound	IC ₅₀ ± SD (μM)		
	HEPG-2	SGC-7901	LS174T
10	78.2±5.7	83.3±5.1	>100
11	>100	>100	89.3±4.3
12a	59.1±6.9	64.1±6.0	>100
12b	66.8±5.5	>100	>100
12c	31.3±7.0	51.8±4.5	84.0±8.8
12d	>100	53.3±8.1	67.3±5.4
12e	6.1±1.5	9.2±2.0	8.0±1.9
12f	13.3±3.9	21.3±4.0	23.6±3.8
12g	8.1±2.3	29.6±5.2	16.7±2.8
13a	76.3±5.6	45.0±6.6	62.2±9.0
13b	63.7±5.4	>100	>100
13c	25.7±4.1	73.9±3.7	49.0±6.6
13d	66.5±7.8	>100	69.5±9.3
13e	57.0±4.5	68.9±5.3	>100
13f	82.4±7.1	>100	51.0±4.2
13g	56.8±9.2	53.8±6.8	>100
Doxorubicin	1.4±0.3	2.1±0.2	1.2±0.3

Note: Data represented the mean of three experiments in triplicate and are expressed as mean ± SD.

Abbreviation: IC₅₀, 50% inhibitory concentration.




Figure 2 Effects of compound **12e** on the morphology of HEPG-2 cells stained by AO/EB.

Notes: After being treated with compound **12e** for 24 h, HEPG-2 cells were stained by AO/EB and morphologies were immediately observed using fluorescence microscopy. Viable cells presented homogeneously stained green nuclei. Early apoptotic cells showed greenish yellow nuclei and late apoptotic cells indicated condensed orange nuclei.

Abbreviations: AO, acridine orange; EB, ethidium bromide.

total apoptotic cells (Figure 3). These results demonstrated that compound **12e** caused a dose-dependent induction of apoptosis in HEPG-2 cells.

Loss of MMP

It is well known that altered mitochondrial function is linked to apoptosis. In particular, loss of MMP can lead to mitochondrial dysfunction and has been regarded as an important factor in controlling the induction of apoptosis.²⁴ To assess the involvement of disruption of MMP in the apoptotic action of compound **12e**, the cationic lipophilic dye, JC-1, which readily penetrates the plasma membrane into cells and accumulates in actively respiring mitochondria, was used to evaluate the disruption of MMP in HEPG-2 cells. Loss of MMP was observed in HEPG-2 cells 48 h after treatment with 6, 12, and 24 μM **12e**. The values observed at these doses decreased to 82.33%, 72.67%, and 55.36%, respectively, of

the value associated with untreated control cells (Figure 4). These findings suggest that apoptosis induced by compound **12e** in HEPG-2 cells is associated with depolarization of the mitochondrial membrane.

Caspase activation induced by compound **12e**

During the process of apoptosis, mitochondrial disruption leads to the release of cytochrome *c*, forming apoptosomes with Apaf-1 and procaspase-9, and triggering caspase-9 activation, which subsequently cleaves the effector caspase-3.²⁵ Western blotting analysis revealed that compound **12e** markedly increased the levels of caspase-9 and the effector cleaved caspase-3 in a concentration-dependent manner (Figure 5). These data suggest that compound **12e** induces apoptosis of HEPG-2 cells via the intrinsic pathway.




Figure 3 Flow cytometric analysis of compound **12e** induced apoptosis in HEPG-2 cells using Annexin V/PI double-staining assay.

Notes: Treatment with compound **12e** at 0 μM , 6 μM , 12 μM , and 24 μM for 48 h followed by staining with FITC-conjugated Annexin V and PI for flow cytometric analysis. Early apoptotic cells are Annexin V positive but PI negative (low right quadrant); late apoptotic and necrotic cells are Annexin V and PI positive (upper right quadrant), and the rate of total apoptosis was the sum of early and late apoptosis. **(A)** Representative flow cytometric plots. **(B)** Flow cytometric analysis result. Data are presented as mean \pm SD ($n=3$), and the significance was established at $***P<0.01$ compared with the control group.

Abbreviations: FITC, fluorescein isothiocyanate; PI, propidium iodide.




Figure 4 Loss of MMP induced by compound **12e** in HEPG-2 cells.

Notes: Cells were treated with 0, 6, 12, and 24 μM **12e** for 48 h and incubated with MMP indicator JC-1. JC-1 dye-stained cells were analyzed by flow cytometry, and the relative red/green fluorescence ratio in treated cells is expressed graphically as a percentage of red/green fluorescence ratio value of the control cells. Each value represents mean ± SD (n=3). **P<0.01 compared with the control group.

Abbreviations: JC-1, 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethyl-imidacarbocyanine iodide; MMP, mitochondrial membrane potential.

Conclusion

A series of novel 4-methoxy-substituted and 5-methyl-substituted (3'S,4'S)-(-)-*cis*-khellactone derivatives were synthesized, characterized, and evaluated for their cytotoxic activities against three human cancer cell lines (HEPG-2, SGC-7901, and LS174T). The results revealed that 4-methoxy-substituted compounds showed potent inhibitory activity. In particular, compound **12e** exhibited highest antitumor activity against the HEPG-2 cancer cell line, and the cytotoxic activity of this new agent could be attributed to its induction of apoptosis possibly via the change in MMP. Furthermore, the upregulation of caspase-9 and cleavage of caspase-3 were shown by Western blot analysis. Collectively, these data show that compound **12e** induces apoptosis via a mitochondria-related caspase-dependent pathway. Hence, compound **12e** could be used as a prototype for further modifications to develop new more active antitumor analogs.




Figure 5 Effect of compound **12e** on the protein expression of cleaved caspase-3 and caspase-9 by Western blot analysis.

Acknowledgments

This study was supported by Program for the Top Young Academic Leaders of Higher Learning Institutions of Shanxi, the Collaborative Innovation Center Project of Shanxi "Astragalus" Resource Industrialization and Industrial Internationalization (No HQXTCXZX2016-021), and Shanxi Natural Science Foundation (No 2016011112). We would also like to thank the support and help from all the teachers of School of Pharmaceutical Science, Shanxi Medical University.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Ferlay J, Soerjomataram I, Ervik M, et al [homepage on the Internet]. International Agency for Research on Cancer; 2013. Available from: <http://globocan.iarc.fr>. Accessed December 18, 2013.
2. Wang HJ. Lapatinib for the treatment of breast cancer in the People's Republic of China. *Onco Targets Ther*. 2014;7:1367–1373.
3. Shahbazian D, Sznol J, Kluger HM. Vertical pathway targeting in cancer therapy. *Adv Pharmacol*. 2012;65(2012):1–26.
4. Kinghorn AD, Chin YW, Swanson SM. Discovery of natural product anticancer agents from biodiverse organisms. *Curr Opin Drug Discov Devel*. 2009;12(2):189–196.
5. Borges F, Roleira F, Milhazes N, Santana L, Uriarte E. Simple coumarins and analogues in medicinal chemistry: occurrence, synthesis and biological activity. *Curr Med Chem*. 2005;12(8):887–916.
6. Fylaktakidou KC, Hadjipavlou-Litina DJ, Litinas KE, Nicolaidis DN. Natural and synthetic coumarin derivatives with anti-inflammatory/antioxidant activities. *Curr Pharm Des*. 2004;10(30):3813–3833.
7. Riveiro ME, De Kimpe NA, Moglioni A, et al. Coumarins: old compounds with novel promising therapeutic perspectives. *Curr Med Chem*. 2010;17(13):1325–1338.
8. Takata M, Shibata S, Okuyama T. Structures of angular pyranocoumarins of Bai-Hua-Qian-Hu, the root of *Peucedanum praeruptorum*. *Planta Med*. 1990;56(3):307–311.
9. Chen ZX, Huang BS, She QL, Zeng GF. The chemical constituents of Bai-Hua-Qian-Hu, the root of *Peucedanum praeruptorum* Dunn. (Umbelliferae)-four new coumarins. *Yao Xue Xue Bao*. 1979;14(8):486–496.
10. Ishii H, Okada Y, Baba M, Okuyama T. Studies of coumarins from the Chinese Drug Qianhu, XXVII: structure of a new simple coumarin glycoside from Bai-Hua Qianhu, *Peucedanum praeruptorum*. *Chem Pharm Bull*. 2008;56(9):1349–1351.
11. Lee T, Kashiwada Y, Huang L, Snider J, Cosentino M, Lee K. Suksdorfii: an anti-HIV principle from *Lomatium suksdorfii*, its structure-activity correlation with related coumarins, and synergistic effects with anti-AIDS nucleosides. *Bioorg Med Chem*. 1994;2(10):1051–1056.
12. ITsai IL, Wun MF, Teng CM, Ishikawa T, Chen IS. Anti-platelet aggregation constituents from Formosan *Toddalia asiatica*. *Phytochemistry*. 1998;48(8):1377–1382.
13. Kozawa T, Sakai K, Uchida M, Okuyama T, Shibata S. Calcium antagonistic action of a coumarin isolated from "Qian-Hu", a Chinese traditional medicine. *J Pharm Pharmacol*. 1981;33(5):317–320.
14. Wu JYC, Fong WF, Zhang JX, et al. Reversal of multidrug resistance in cancer cells by pyranocoumarins isolated from *Radix Peucedani*. *Eur J Pharmacol*. 2003;473(1):9–17.
15. Shen X, Chen G, Zhu G, et al. 3'-O, 4'-O-aromatic acyl substituted 7,8-pyranocoumarins: a new class of P-glycoprotein modulators. *J Pharm Pharmacol*. 2012;64(1):90–100.

16. Huang L, Kashiwada Y, Cosentino ML, et al. Anti-AIDS agents. 15. Synthesis and anti-HIV activity of dihydroseselin and related analogs. *J Med Chem*. 1994;37(23):3947–3955.
17. Yu D, Suzuki M, Xie L, Morris-Natschke SL, Lee KH. Recent progress in the development of coumarin derivatives as potent anti-HIV agents. *Med Res Rev*. 2003;23(3):322–345.
18. Xie L, Takeuchi Y, Cosentino LM, Lee KH. Anti-AIDS agents. 37. Synthesis and structure–activity relationships of (3'R,4'R)-(+)-cis-khellactone derivatives as novel potent anti-HIV agents. *J Med Chem*. 1999;42(14):2662–2672.
19. Takeuchia Y, Xie L, Cosentino LM, Lee KH. Anti-AIDS agents-XXVIII.¹ Synthesis and anti-HIV activity of methoxy substituted 3',4'-Di-O-(–)-camphanoyl-(+)-cis-khellactone (DCK) analogues. *Bioorg Med Chem Lett*. 1997;7(20):2573–2578.
20. Xie L, Yu DL, Wild C, et al. Anti-AIDS agents. 52. Synthesis and anti-HIV activity of hydroxymethyl (3'R,4'R)-3',4'-Di-O-(S)-camphanoyl-(+)-cis-khellactone derivatives. *J Med Chem*. 2004;47(3):756–760.
21. Ren LH, Du X, Hu MN, Yan CQ, Liang TG, Li QS. Design, synthesis and antitumor activity of novel 4-methyl-(3'S,4'S)-cis-khellactone derivatives. *Molecules*. 2013;18(4):4158–4169.
22. Tembe SB, Bhedi DN, Souza NJ, Rupp RH. Synthesis of (±)-praeruptorin A and related khellactone derivatives. *Heterocycles*. 1987;26(5):1239–1249.
23. Xie L, Crimmins MT, Lee KH. Asymmetric synthesis of 3',4'-Di-O-(–)-camphanoyl-(+)-Cis-khellactone (DCK), a potent anti-HIV agent. *Tetrahedron Lett*. 1995;36(26):4529–4532.
24. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. *Physiol Rev*. 2007;87(1):99–163.
25. Kim HE, Du F, Fang M, Wang X. Formation of apoptosome is initiated by cytochrome c-induced dATP hydrolysis and subsequent nucleotide exchange on Apaf-1. *Proc Natl Acad Sci U S A*. 2005;102(49):17545–17550.

Supplementary material




Figure S1 In vitro cytotoxicity of compound **12e** on HL-7702 normal human hepatocyte.

Note: The toxicity of compound **12e** to normal human liver cells was observed by MTT assay at the concentration of 25, 50, 100, and 200 μM for 48 h.

Drug Design, Development and Therapy

Dovepress

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are the features of the journal, which

has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/drug-design-development-and-therapy-journal>